782 results about "Pathogenicity" patented technology

The invention belongs to the technical field of RNA biological prevention and treatment, and particularly relates to dsRNA for preventing and treating crop anthracnose and application of the dsRNA. The dsRNA is targeted inositol phosphatidylceramide (IPC) synthetase coding gene dsRNA, and is obtained by transcription of a part of sequence (SEQ ID No.1) of an inositol phosphatidylceramide (IPC) synthetase coding gene CaAUR1, the gene segment is a segment of a target gene for preventing and treating crop anthracnose, and the dsRNA obtained by transcription can obviously reduce pathogenicity of mango anthracnose bacteria, and has the effects of keeping mango fresh, preventing and treating anthracnose. And the compound can be used for preventing and treating the crop anthracnose or preparing products for preventing and treating the crop anthracnose.

The present invention relates to a computer-implemented multi-module classifier method and system for providing a pathogenicity classification score of a variant of a protein of interest. The classifier comprises a sequence module based on a protein language model (PLM); a structure module based on a graph neural network (GNN); a property module; and a unified head module based on a machine learning model. The invention further relates to methods for preparing, training, and implementing the multi-module classifier system.

The invention discloses an identification and analysis method for unknown pathogenic microorganisms, which comprises the following steps: filtering out genome sequences with low integrity, pollution and tag errors, and establishing a high-quality virus identification database; constructing a virus host prediction model through a machine learning algorithm; unknown pathogenic microorganisms are identified and analyzed, potential hosts or pathogenicity of the unknown microorganisms are identified, and whether the unknown microorganisms are unknown pathogenic viruses or bacteria or not is further judged. On the basis of metagenome data analysis, potential unknown pathogenic microorganisms in samples of human bodies, environments and the like can be identified more accurately.

The invention discloses a recombinant subunit vaccine for resisting trichomonas pigeonae infection and a preparation method of the recombinant subunit vaccine. The vaccine comprises two recombinant proteins with sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8 respectively and a pharmaceutically acceptable carrier. According to the invention, Sf9 cells are used for respectively expressing trichomonas pigeonae adhesion protein 33 and adhesion protein 65, the immunogenicity of the obtained recombinant protein is similar to that of natural protein, the expression level is high, the immunogenicity is strong, a very small amount of recombinant protein can provide a better immune protection effect, and the recombinant protein has no pathogenicity to pigeons, and can be used for preparing the recombinant protein for preventing and treating trichomonas pigeonae. Meanwhile, large-scale serum-free suspension culture can be carried out through a bioreactor, so that the vaccine production cost is greatly reduced.

The invention discloses acinetobacter baumannii and application of the acinetobacter baumannii in construction of a mastitis animal model. The acinetobacter baumannii strain is acinetobacter baumannii AbST3475NMG202308, and the preservation number of the acinetobacter baumannii strain is CGMCC (China General Microbiological Culture Collection Center) No.34450 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the acinetobacter baumannii has high pathogenicity and can be used for establishing a typical animal model caused by acinetobacter baumannii infection, the animal model can be specifically a mastitis animal model, and a certain technical support is provided for subsequent research and development of drugs or vaccines; the acinetobacter baumannii can also be used for screening antibacterial drugs and developing diagnostic reagents and vaccines. The method has an important application value.

The invention discloses dsRNA of a targeted BdSpt7 gene, a biocontrol agent and application of the dsRNA. The sequence of the dsRNA of the targeted BdSpt7 gene is as shown in SEQ ID No.2. The invention further discloses a preparation method of the biocontrol agent of the targeted BdSpt7 gene. The active ingredient of the biocontrol agent is the dsRNA of the target BdSpt7 gene. The invention also provides an application of the botryosphaeria dothidea BdSpt7 gene in prevention and treatment of apple botryosphaeria dothidea, and a nucleotide sequence of the botryosphaeria dothidea BdSpt7 gene is shown as SEQ ID No.1. The invention also provides an African trichoderma harzianum engineering strain for expressing dsRNA, the African trichoderma harzianum engineering strain is integrated with a dsRNA expression box for interfering gene expression of a target gene BdSpt7, the dsRNA expression box is shown as SEQ ID No.1, and the African trichoderma harzianum is an African trichoderma harzianum with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 41709. The dsRNA targeting the BdSpt7 gene can significantly reduce the pathogenicity of the physalospora piricola through interference, and the African trichoderma harzianum engineering strain can colonize on the plant surface and continuously express the dsRNA so as to play a role in preventing and treating the physalospora piricola, and is green and environment-friendly.

The invention discloses a VdNOB1 gene as well as an anti-pathogenic bacterium target gene segment, an interference vector and disease-resistant application thereof. According to the invention, the VdNOB1 gene is subjected to knockout mutation, so that the infection pathogenicity of verticillium dahliae to host plants can be obviously reduced. The invention further provides a verticillium dahliae VdNOB1 gene anti-pathogenic bacterium target gene segment, the nucleotide sequence of the verticillium dahliae VdNOB1 gene anti-pathogenic bacterium target gene segment is shown as SEQ ID No.4, and the pathogenicity of verticillium dahliae to host plants can be remarkably reduced after plants are transformed by an RNA interference vector constructed by the verticillium dahliae VdNOB1 gene anti-pathogenic bacterium target gene segment. The invention further provides an RNA (Ribonucleic Acid) interference vector containing the VdNOB1 gene or an anti-pathogenic bacterium target gene fragment thereof. The verticillium dahliae VdNOB1 gene or the anti-pathogenic-bacterium target gene segment and the RNA interference vector thereof have application prospects in the aspects of improving the resistance of crops to diseases caused by verticillium dahliae, cultivating new varieties of verticillium dahliae-resistant plants and the like.

The invention discloses a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection kit for prawn culture pathogenic bacteria, which is characterized in that the kit contains primers and probes for detecting the prawn culture pathogenic bacteria, wherein the primers and the probes are respectively used for detecting TDH-related hemolsin genes of vibrio parahaemolyticus, ORF107 genes of white spot syndrome viruses, small subunit ribosomal genes of shrimp enterocytozoon hepatopenaei, 37 kDa coat protein genes of infectious subcutaneous and hematopoietic necrosis viruses, DNA (deoxyribonucleic acid) primer genes of full-eye iridovirus 1 and PirA [pi] genes of pathogens of bacterial prawns acute hepatopancreas necrosis; the method has the advantage that the detection of eight prawn culture pathogens can be realized at the same time. The method comprises the following steps of: obtaining a tcdB gene of a high-pathogenicity vibrio and a hemolsin gene of a vibrio harveyi;

The invention discloses application of epimedin A in preparation of a streptococcus suis type 2 capsule inhibitor, and belongs to the technical field of biological medicine. The compound can effectively inhibit the synthesis function of the streptococcus suis type 2 capsule, further enhances the removal effect of a host on the streptococcus suis type 2, reduces the pathogenicity of bacteria, and provides a new candidate compound and idea for preparing a capsule inhibitor of the streptococcus suis type 2 and researching and developing a novel medicine for treating streptococcus suis type 2 infection.

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

The present disclosure provides a systems and methods for processing genetic variations and phenotypic data. The systems and methods may be used to generate one or more databases comprising genetic variations and associations with phenotypes. The system and methods may be used to determine a pathogenicity of a genetic variation. The systems and methods may comprise human interpretation using pre-determined criteria.

The invention discloses a new mutation-oriented pathogenicity prediction method, which comprises the following steps of: acquiring new mutation site data to be analyzed, and generating a numerical feature vector containing evolution conservative property, function prediction score and quantitative clinical evidence; constructing a feature extractor through the numerical feature vector; inputting a training data set containing a label sample and a label-free sample into the feature extractor, and updating the network parameters of the feature extractor and each header; and predicting target variation by using the feature extractor after parameter updating and the supervised classification head to obtain a pathogenicity probability, and calculating a contribution value of each feature in the numerical feature vector to the pathogenicity probability. According to the technical scheme provided by the invention, the auxiliary decision-making information conforming to the diagnosis habit of a doctor is output, the workload of manually interpreting the variation with unclear meaning is greatly reduced, and the end-to-end intelligent processing from the original sequencing data to the clinical auxiliary diagnosis is realized.

The invention provides application of lactobacillus rhamnosus GOLDGUT-M520 or a composition of the lactobacillus rhamnosus GOLDGUT-M520 in preparation of a product for enhancing the immunity of an organism. The lactobacillus rhamnosus GOLDGUT-M520 has the function of enhancing the immunity in both a viable form and an inactivated form of the lactobacillus rhamnosus GOLDGUT-M520. The lactobacillus rhamnosus GOLDGUT-M520 has a good antibacterial capability on escherichia coli and staphylococcus aureus which are pathogenic to intestinal tracts, and is beneficial to enhancing a chemical barrier in an innate immune barrier; the strain can improve the phagocytic activity of macrophages and enhance the innate immune response; the strain can improve the T cell proportion, the B cell proportion and the immune globulin level in mesenteric lymph nodes of immunocompromised mice, and can enhance adaptive immune response. The lactobacillus rhamnosus GOLDGUT-M520 can comprehensively play a role in enhancing immunity, and meanwhile, the inherent immune barrier, the inherent immune response and the adaptive immune response are enhanced.

The invention relates to the technical field of biology, and discloses an FPSE09041 protein and an application of a coding gene of the FPSE09041 protein in reducing pathogenicity of fusarium pseudograminearum. The amino acid sequence of the FPSE09041 protein is as shown in SEQ ID NO. 2, and the coding gene of the FPSE09041 protein is as shown in SEQ ID NO. 1. By knocking out the FPSE09041 gene, the expression of the FPSE09041 protein is inhibited, and the pathogenicity of the fusarium pseudograminearum to host plants is reduced. The research finds that the FPSE09041 is an indispensable key factor for pathogenicity of the fusarium pseudograminearum, and the survival and infection capabilities of pathogenic bacteria can be obviously weakened due to function deficiency of the FPSE09041. Therefore, the FPSE09041 protein and the coding gene thereof can be used as ideal molecular targets for developing novel, efficient and high-specificity antifungal agents, and a new technical path is provided for green prevention and control of wheat stem rot.

The invention provides acinetobacter for culturing prawns in saline-alkali water and application of the acinetobacter. The preservation number of the provided acinetobacter is CGMCC (China General Microbiological Culture Collection Center) No.36066. The acinetobacter soilis strain provided by the invention has remarkable comprehensive application advantages, can still keep higher growth activity and metabolic capability in a low-temperature environment, and continuously plays a water body purification function. Ammonia nitrogen and nitrite nitrogen in a water body can be efficiently degraded, the environment of the aquatic water body is remarkably improved by promoting the nitrogen circulation process, and harm caused by nitrogen pollution is reduced. In addition, the strain can effectively inhibit and prevent reproduction of pathogenic vibrios and reduce the occurrence risk of bacterial diseases of aquatic animals. The strain is high in safety, does not cause poison or stress reaction to bred animals even under the condition of high-concentration use, and has good ecological safety and environmental friendliness.

The invention belongs to the technical field of prevention and treatment of rice blast, and particularly relates to a polypeptide MP1 for inhibiting rice blast bacteria and application thereof. The invention discloses a polypeptide MP1 for inhibiting magnaporthe oryzae. The amino acid sequence of the polypeptide MP1 is as shown in SEQ ID NO. 1. The polypeptide MP1 has an obvious inhibition effect on the magnaporthe oryzae appressorium, and the EC50 formed by the MP1 polypeptide on the appressorium is 134.60 mu M. Experiments show that the polypeptide can effectively interfere the normal differentiation and development of the appressorium in the key pathogenic stage of magnaporthe oryzae, so that the polypeptide has a strong prevention and control potential in the early stage of pathogenic bacterium infection. The polypeptide MP1 provided by the invention can significantly reduce the pathogenicity of magnaporthe oryzae to barley and rice, and provides an experimental basis for developing a novel biopesticide for preventing and treating the magnaporthe oryzae.

The invention belongs to the technical field of pathogenic microorganism screening, and particularly relates to vibrio parahaemolyticus capable of causing prawn vibrio vitreovibriosis and application of the vibrio parahaemolyticus, and the pathogenic bacteria can be used for preparing inactivated vaccines or used as the pathogenic bacteria to screen medicine components with the effect of preventing and treating the prawn vibrio vitreovibriosis or a culture method. The preservation number of the vibrio parahaemolyticus provided by the invention is CGMCC (China General Microbiological Culture Collection Center) The pathogenicity of the vibrio parahaemolyticus with high pathogenicity and strong lethality is about 1000 times stronger than that of the vibrio parahaemolyticus which is collected by the world animal hygiene organization and causes acute hepatopancreatic necrosis, and the strain is popular in main prawn culture areas and causes serious harm to the prawn fry culture industry in China. The vibrio parahaemolyticus provided by the invention can be used as a positive control for preparing a diagnosis product for the prawn vibrio vitreovirus disease; or preparing an immune vaccine after inactivation.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

The invention relates to the technical field of agricultural biology, in particular to a verticillium dahliae heat shock protein 90 ATP enzyme activating factor VdAHA1 as well as a coding gene and application of the verticillium dahliae heat shock protein 90 ATP enzyme activating factor VdAHA1. The invention provides a verticillium dahliae heat shock protein 90 ATP enzyme activating factor VdAHA1 related to high temperature resistance, drug resistance, environmental adaptability, ergosterol synthesis capability and pathogenicity of verticillium dahliae and a coding gene of the VdAHA1, and the VdAHA1 gene positively regulates the pathogenicity of verticillium dahliae and can be used as an important candidate gene for pathogenesis research of verticillium dahliae. The invention provides a theoretical basis for further understanding the pathogenic mechanism of pathogenic bacteria, also provides a new gene resource for verticillium dahliae pathogenic related genes, also provides a new idea for prevention and control of cotton verticillium wilt, and has a wide application prospect.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of UH15-38 in preparation of a medicine for preventing and treating PEDV-PoRVA co-infection. According to the invention, a PEDV and PoRVA co-infected piglet model is systematically established for the first time, a high-throughput transcriptomics means is combined, an enhancement mechanism of co-infection on host pathogenicity is deeply analyzed from an immune regulation level, and based on the mechanism, UH15-38 is found to be capable of effectively treating PEDV and PoRVA co-infected piglets. Experimental data show that the UH15-38 remarkably relieves clinical diarrhea symptoms caused by co-infection, reduces the copy number of PoRVA and PEDV viruses, effectively inhibits duplication of the viruses in intestinal tracts, remarkably reduces the expression levels of IL-1beta and p-MLKL in jejunum tissues, and reduces necrotic apoptosis and inflammatory response. The UH15-38 can provide a new application value for the treatment of the porcine viral diarrhea.

The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.

The invention discloses a monogenic disease genetic variation intelligent interpretation method and device and a medium, and relates to the technical field of bioinformatics, and the method comprises the steps: generating an enhanced similarity matrix through a disease-specific phenotype template and a cosine similarity algorithm based on a standardized phenotype feature vector, and obtaining a dynamic weight vector through a dynamic adjustment function; integrating the dynamic weight vector into a normalized multi-omics data matrix, calculating a preliminary disturbance score through a path integral formalization algorithm, and obtaining a path disturbance score; and fusing the pathway disturbance score and the dynamic weight vector, calculating a pathogenicity score through a multi-level evidence fusion algorithm inspired by a quantum field theory, and generating a comprehensive report of variation pathogenicity grading and clinical suggestions according to a thermodynamic partition function model. According to the method, nonlinear and high-dimensional collaborative modeling and thermodynamic stability optimization of heterogeneous biological evidence are realized, and the interpretability of pathogenicity judgment under a complex genetic background is also improved.

The invention discloses a bacillus safensis strain and application thereof in aquaculture, and relates to the technical field of aquaculture disease prevention and control, the obtained bacillus safensis strain ZY-1 forms spores under a certain fermentation condition, can be prepared into powder for preservation, has a long shelf life, has the bacteriostatic activity retention rate of more than or equal to 85% after being stored in a dark place for 12 months at 4-25 DEG C, and has the antibacterial activity of more than or equal to 7.2%. The production, transportation and storage cost is saved, main bacteriostatic effect factors of the bacillus safensis ZY-1 strain exist in extracellular metabolites, the bacillus safensis ZY-1 strain is stable in performance and resistant to high temperature, acid and alkali, ultraviolet rays, protease and the like, and fermentation supernatant of the bacillus safensis ZY-1 strain can be directly applied or prepared into spray-dried powder and is suitable for various aquaculture application scenes such as pond splashing and feed mixing and feeding. The metabolite spray-dried powder has a remarkable killing effect on high-pathogenicity vibrios VpAHPND and VpTPD, the minimum inhibitory concentrations of metabolite spray-dried powder respectively reach 23.44-46.88 mu g / ml and 46.88-93.75 mu g / ml, and the metabolite spray-dried powder can be used for preventing and controlling prawn infectious hepatopancreas necrosis and prawn transparent larva diseases induced by the metabolite spray-dried powder and also has a certain killing function on pathogens of other aquatic animals.

The invention mainly provides Beauveria bassiana ZABb200102 and application of the Beauveria bassiana ZABb200102, the Beauveria bassiana ZABb200102 is preserved in China General Microbiological Culture Collection Center on October 28, 2024, and the preservation number of the Beauveria bassiana ZABb200102 is CGMCC (China General Microbiological Culture Collection Center) No. 41557. The strain is separated from sick lepidoptera cacalidae larva bodies for the first time, and it is found through toxicity determination that the strain has high pathogenicity to tomato leaf miner larvae. In addition, the strain can also be colonized in tomatoes, so that the growth of the tomatoes is promoted, and the resistance of the tomatoes to pests is indirectly improved. Therefore, the strain can be widely applied to development of tomato bacterial fertilizer and green prevention and control of tomato leaf miner which is an important tomato pest.

The invention provides a rhodopseudomonas palustris antibacterial peptide, an antibacterial product and application, and belongs to the technical field of biological prevention and treatment medicine manufacturing. According to the application disclosed by the invention, two functional short peptides, namely KKKYG and VVGRR, with remarkable fungal antagonism activity are identified from extracellular polypeptide components of rhodopseudomonas palustris for the first time. Experiments prove that the two types of oligopeptides not only can effectively inhibit the formation of magnaporthe oryzae appressorium, but also can obviously weaken the pathogenicity of the oligopeptides on rice hosts and inhibit the pathogenicity of magnaporthe oryzae on rice, and have potential broad-spectrum antagonistic fungal activity and excellent biological control potential. The functional oligopeptide liquid preparation or freeze-dried powder prepared on the basis of the method is non-toxic to people and livestock, has no phytotoxicity to crops, does not pollute the environment, and meets the core requirements of green agriculture and sustainable development; and the oligopeptide preparation shows good heat-resistant stability, is convenient to store and transport, and adapts to complex and changeable field environments.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The invention relates to a disease-specific quantitative trait locus identification method based on multi-omics integration. The method comprises the following steps: acquiring variation sites of whole genome sequencing data of a target object, and molecular phenotypes and molecular abundance of molecular phenotype data; determining an association significance probability value of an association pair formed by the variation point and the molecular phenotype based on the variation point and the molecular abundance, and screening a first association pair from the association pair based on the association significance probability value and condition analysis; determining a consistent second association pair in the normal association pair and the disease association pair, and determining a third association pair with a disease interaction effect in the second association pair; calculating a first effect estimation value and a second effect estimation value of each third association pair; and based on the first effect estimation value and the second effect estimation value of the third correlation pair, determining a target correlation pair related to the Parkinson's disease, and taking the target correlation pair as the identified quantitative trait site. By adopting the method, the Parkinson's specific pathogenic heritable variation can be accurately identified.

The invention discloses an application of a small peptide GLP-1 (28-36) amide in preparation of a medicine for preventing and treating rice blast and a method of the small peptide GLP-1 (28-36) amide. The invention discloses an application of the small peptide GLP-1 (28-36) amide in preparation of a medicine for preventing and treating magnaporthe oryzae, and an application of the small peptide GLP-1 (28-36) amide in inhibition of magnaporthe oryzae and prevention and treatment of magnaporthe oryzae. The small peptide GLP-1 (28-36) amide can effectively inhibit pathogenicity of pyricularia oryzae spores in the concentration range of 12.5-100 [mu] M, especially the small peptide GLP-1 (28-36) amide with the concentration of 100 [mu] M can completely prevent and treat pyricularia oryzae, and the small peptide GLP-1 (28-36) amide can be used for developing novel green pesticides.

Novel strains of the insect-pathogenic fungus, Metarhizium var. anisopliae fungal strain BNL 101 deposited in the CABI UK Centre, United Kingdom, having IMI CC Number 506833; or BNL 102 deposited in the CABI UK Centre, United Kingdom, having IMI CC Number 506834; or a culture having the identifying characteristics thereof, are disclosed. The present invention also discloses methods of using the fungal strains, and spores obtained therefrom, to control insects, and provides a natural pest control preparation. The preparations and compositions comprise several unique and desirable features, such as a wide host range or alternatively a selective host range, and a consistent pathogenicity. The preparations and compositions have a high virulence (insecticidal activity), that is 2 times to 3 times, or greater, mor virulent (insecticidal) than compositions or preparations that do not contain the preparation or composition, and especially that do not contain the BNL 101 or BNL 102 fungal strain, or spores therefrom. The fungal strains also provide for a high spore yield in production, and possess a high stability in the field.